

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: David WALLACH et al

Art Unit: 1644

Application No.: 08/485,129

Examiner: R. Schwadron

Filed: June 7, 1995

Washington, D.C.

For: ISOLATED DNA ENCODING TUMOR NECROSIS FACTOR BINDING PROTEIN, ...

Atty.'s Docket: WALLACH=5B

Date: November 6, 2000

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [X] Amendment []
in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[] No additional fee is required.

[XX] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 31	MINUS	** 21		10
INDEP.	* 8	MINUS	*** 5		3
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 40	\$
+ 135	\$
ADDITIONAL FEE TOTAL	
	\$

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$ 180.00
x 80	\$ 240.00
+ 270	\$
TOTAL	
	\$ 420.00

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity
Response Filed Within
[] First - \$ 55.00
[] Second - \$ 195.00
[] Third - \$ 445.00
[] Fourth - \$ 695.00
Month After Time Period Set

Other Than Small Entity
Response Filed Within
[] First - \$ 110.00
[XX] Second - \$ 390.00
[] Third - \$ 890.00
[] Fourth - \$ 1390.00
Month After Time Period Set

[] Less fees (\$) already paid for month(s) extension of time on .

[] Please charge my Deposit Account No. 02-4035 in the amount of \$.


[XX] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ 810.00 .

[] A check in the amount of \$ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: 
Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

#361 11/18/00
TBray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

WALLACH et al

Appln. No.: 08/485,129

Filed: June 7, 1995

For: ISOLATED DNA ENCODING
TUMOR NECROSIS FACTOR
BINDING PROTEIN II, AND
VECTORS, HOSTS AND
PROCESSES USING SUCH DNA



Art Unit: 1644

Examiner: R. Schwadron

Washington, D.C.

November 6, 2000

Atty. Docket: WALLACH=5B

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of June 6, 2000,
petition for a two-month extension of time and payment of the
late fee being attached hereto, please amend as follows:

IN THE CLAIMS

Please insert the following new claims:

--52. An isolated DNA molecule comprising a
contiguous nucleotide sequence coding for a naturally occurring
human Tumor Necrosis Factor (TNF) binding protein (TBP-II)
having the following characteristics:

- (a) includes the amino acid sequence Thr-Pro-Tyr-
Ala-Pro-Glu-Pro-Gly-Ser-Thr in the portion of
the protein sequenced by N-terminal sequence
analysis; and

11/07/2000 SDUONG 00000059 08485129

01 FC:102 240.00 OP
02 FC:103 180.00 OP
03 FC:116 390.00 OP